Publication | Closed Access
5‐azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors
46
Citations
32
References
2010
Year
So, this study strongly suggests a therapeutic potential of 5-Aza in combination with anti-androgen therapy in patients with in AR expressing and AR-deficient HRPC.
| Year | Citations | |
|---|---|---|
Page 1
Page 1